Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer

BACKGROUND: Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express...

Descripción completa

Detalles Bibliográficos
Autores principales: Viale, G., Basik, M., Niikura, N., Tokunaga, E., Brucker, S., Penault-Llorca, F., Hayashi, N., Sohn, J., Teixeira de Sousa, R., Brufsky, A.M., O’Brien, C.S., Schmitt, F., Higgins, G., Varghese, D., James, G.D., Moh, A., Livingston, A., de Giorgio-Miller, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515285/
https://www.ncbi.nlm.nih.gov/pubmed/37562195
http://dx.doi.org/10.1016/j.esmoop.2023.101615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515285/
https://www.ncbi.nlm.nih.gov/pubmed/37562195
http://dx.doi.org/10.1016/j.esmoop.2023.101615

Ejemplares similares